Background and Objectives: Cancer imposes a profound burden on both physical and psychological health, particularly at advanced stages, which are associated with a poor prognosis and heightened emotional distress. Psychotherapeutic interventions have gained recognition for their role in alleviating distress, enhancing the quality of life, and supporting a holistic approach to cancer care. This review examines the effectiveness of psychotherapeutic interventions in improving psychological well-being in cancer patients. Materials and Methods: Conducted as a literature review following PRISMA guidelines, this study analyzed experimental research on psychotherapeutic interventions for cancer patients published in the past decade. Literature searches were performed in PubMed, Google Scholar, the Cochrane Library, Web of Science, PsycINFO, and Consensus, supplemented by manual reference checks. The inclusion criteria focused on randomized controlled trials (RCTs). Results: The analysis included 20 RCTs spanning over three decades, evaluating interventions such as individual meaning-centered psychotherapy (IMCP), Mindfulness-Based Cognitive Therapy (MBCT), and supportive–expressive group therapy (SEGT). IMCP emerged as being particularly effective in reducing depression, anxiety, and demoralization while enhancing spiritual well-being. MBCT demonstrated significant reductions in the fear of recurrence, while SEGT effectively addressed traumatic stress and fostered social support. Although the survival benefits were inconsistently reported, psychosocial improvements, including an enhanced quality of life and emotional resilience, were consistently observed. The methodological quality varied, with nine studies meeting high-quality standards. Conclusions: Psychotherapeutic interventions, particularly IMCP and MBCT, play a critical role in oncology by alleviating distress, fostering resilience, and improving the quality of life. Integrating these approaches into routine cancer care can ensure a more holistic treatment framework that prioritizes the emotional and psychological needs of patients.

Background and Objectives: This systematic review investigates the relationship between preoperative psychological disorders and postoperative satisfaction among patients undergoing aesthetic surgery. While aesthetic procedures can enhance self-image, growing evidence indicates that underlying mental health conditions, particularly BDD, depression, and anxiety, may compromise surgical outcomes. Materials and Methods: A comprehensive literature search was performed in PubMed, the Cochrane Library, and Google Scholar between January 2010 and December 2024. Eligible observational studies assessed preoperative psychological conditions—primarily body dysmorphic disorder, depression, and anxiety—using validated instruments, such as the Body Dysmorphic Disorder Questionnaire (BDDQ), Body Dysmorphic Disorder Examination (BDDE), Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), and structured clinical interviews, and reported postoperative patient-reported satisfaction following aesthetic surgery. Study quality was evaluated using an adapted QUIPS framework. Results: Across the 13 included studies, six reported a negative association between moderate-to-severe preoperative psychological symptoms and postoperative satisfaction, five found no significant association, and two described positive or conditional associations. Methodological heterogeneity in psychological assessment tools and satisfaction measures was a major source of divergence across studies. Despite these differences, the evidence underscores the need for standardized, validated psychological evaluation protocols in aesthetic surgery. Incorporating mental health screening into routine surgical planning can enhance ethical practice, reduce dissatisfaction, and improve long-term patient outcomes. Conclusions: These findings advocate for a multidisciplinary approach that includes psychological assessment as an essential component of patient care in aesthetic medicine.

Background/Objectives: Cystic fibrosis (CF) is a chronic genetic disease that impacts both physical and psychological health, increasing vulnerability to anxiety, depression, and reduced quality of life (QoL). Psychological interventions, particularly cognitive behavioral therapy (CBT), have demonstrated promising results in enhancing emotional resilience, treatment adherence, and QoL. This systematic review aims to evaluate the role and effectiveness of psychological interventions in improving the QoL among individuals with CF. Methods: A comprehensive literature search was conducted across the PubMed, Scopus, and PsycINFO databases for studies published between 2014 and 2024, in line with PRISMA guidelines and a registered PROSPERO protocol. Out of 162 initially identified articles, six clinical studies met the inclusion criteria. Intervention included cognitive behavioral therapy-based interventions, employing several digital or telehealth formats such as fibrosis-specific cognitive behavioral therapy (CF-CBT) and the coping and learning to manage stress (CALM) program, often delivered via telehealth. Results: Most interventions demonstrated significant reductions in depression, anxiety, and perceived stress, alongside improvements in coping self-efficacy and vitality. Cohen’s d-effect sizes ranged from moderate to large for core psychological outcomes. QoL measures, particularly vitality and emotional functioning, were significantly enhanced in most studies. Conclusions: Psychological interventions, particularly CBT and ACT, significantly improve mental health and QoL in individuals with CF, supporting their integration into routine care.

Background: Emotional intelligence (EI) is an important component of adolescents’ psychological adjustment and social functioning. Creativity-based experiential approaches may support EI development through active emotional processing, reflection, and interpersonal learning; however, empirical evidence in adolescents remains limited. Methods: This quasi-experimental controlled pretest–posttest study included 47 adolescents who self-selected into an experimental group (n = 24) or control group (n = 23) according to their preference regarding participation in the training program. EI was assessed using the Schutte Self-Report Emotional Intelligence Test (SSEIT). The experimental group completed a 12-week creativity-based experiential programme, while the control group continued usual activities. Results: At post-intervention, the experimental group had significantly higher overall EI (p < 0.001, d = 1.60), AES (p < 0.001, d = 1.34), and ERO (p < 0.001, d = 1.24) scores than the control group. Although post-intervention ERS scores were also higher in the experimental group, a large ERS difference was already present at baseline and the experimental group showed no favorable descriptive change in this dimension. Utilization of emotions in problem solving did not differ significantly between groups (p = 0.090, d = 0.50). Conclusions: Participation in creativity-based experiential training was associated with higher post-intervention overall EI, AES, and ERO scores, but demonstrated limited effectiveness for ERS and UEPS. The small sample and insufficient statistical power, together with the non-randomized design and baseline ERS imbalance, preclude firm or causal conclusions. Larger randomized controlled studies using multimethod assessments and long-term follow-up are needed to establish causality, durability, and the mechanisms underlying these associations.

Background/Objectives: Psilocybin-assisted therapy has progressed from early proof-of-concept work to a substantially expanded evidence base, with four pivotal studies published in 2025–2026 that were not incorporated into earlier reviews. This review synthesizes the pharmacological and neurobiological foundations of psilocybin and appraises clinical evidence across major depressive disorder (MDD), treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), cancer-related distress, and substance use disorders, emphasizing long-term durability, expanding indications, and methodological limitations. Methods: A narrative review was conducted using a targeted search of PubMed/MEDLINE, Embase, Scopus, and Web of Science (January 2000–April 2026), emphasizing 2025–2026 publications. Predefined eligibility principles prioritized randomized controlled trials, long-term follow-up studies, and systematic reviews; formal PRISMA procedures were not applied, consistent with the narrative design. Results: Four 2025–2026 studies extend the evidence base: a 52-week follow-up confirming dose-dependent maintenance of antidepressant benefit after a single 25 mg psilocybin session; the first pilot study in Veterans with severe TRD, reporting a 60% response rate at three weeks; the first safety trial in PTSD, where symptom improvement tracked self-transcendent experience intensity but worsened with session anxiety; and a living review of 15 randomized trials confirming a meaningful antidepressant effect while identifying functional unblinding as a substantial threat to effect estimates. Conclusions: Evidence supports psilocybin-assisted therapy as mechanistically distinct and clinically promising, most strongly in MDD and TRD, with preliminary support in PTSD and Veterans. Functional unblinding, small open-label designs, narrow safety populations, and absent SSRI-integration protocols constrain the current conclusions.